Discovery of DCAF16-based PROTACs as SHP2 degraders
Bioorganic Chemistry · 2026-10 · 181 · 110372
DOI: 10.1016/j.bioorg.2026.110372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-10. Verfasst von Xiaojing Pang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian Univers…. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Antineoplastic Agents, Drug Discovery, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Fujian University of Traditional Chinese Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
The overexpression of SHP2 in various cancers establishes it as an attractive therapeutic target. Growing evidence indicates that the scaffold function of SHP2 contributes significantly to its oncogenic signaling and tumorigenesis. Unlike traditional inhibitors, PROTACs can simultaneously eliminate both the enzymatic and scaffold functions of the target protein, representing a more promising therapeutic strategy. Herein, we report the design and synthesis of SHP2 PROTACs that recruit the DCAF16 E3 ligase for targeted SHP2 degradation. Among which, SK8 exhibited the most potent anti-tumor activity. SK8 induced SHP2 degradation in a concentration- and time-dependent manner via the ubiquitin-proteasome system. Notably, under the tested experimental conditions, SK8 produced greater inhibition of cell proliferation, migration, and invasion, together with increased apoptosis, compared with SHP099. Preliminary mechanistic studies revealed that this enhanced potency stemmed from a more profound inhibition of RAS/MAPK and PI3K/AKT/mTOR signaling, coupled with the reversal of IFN-γ/JAK/STAT1 suppression. Overall, our findings support the potential of SHP2-targeted protein degradation as an alternative strategy to enzymatic inhibition and provide a promising starting point for the further development of SHP2 degraders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China; Wuya Colleg…
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Institute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
- Institute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China. Electronic…
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: spuyyy@163.com.
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: syzyclx@163.com.
Förderung
- Fujian University of Traditional Chinese Medicine
- National Natural Science Foundation of China
Zitieren
APA
Pang, X., Gan, Y., Hu, Q., Zheng, W., Liu, Y., Zhang, K., Yang, Y., Chen, L., & Li, H. (2026). Discovery of DCAF16-based PROTACs as SHP2 degraders. Bioorganic Chemistry, 181, 110372. https://doi.org/10.1016/j.bioorg.2026.110372
Vancouver
Pang X, Gan Y, Hu Q, Zheng W, Liu Y, Zhang K, et al. Discovery of DCAF16-based PROTACs as SHP2 degraders. Bioorganic Chemistry. 2026;181:110372. doi:10.1016/j.bioorg.2026.110372
BibTeX
@article{Pang2026,
author = {Pang, Xiaojing and Gan, Yuxin and Hu, Qingyuan and Zheng, Wenshuo and Liu, Yang and Zhang, Kexin and Yang, Yueying and Chen, Lixia and Li, Hua},
title = {Discovery of DCAF16-based PROTACs as SHP2 degraders},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {181},
pages = {110372},
doi = {10.1016/j.bioorg.2026.110372}
}
EUVIMED